Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy
Open Access
- 1 February 1990
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 61 (2) , 323-324
- https://doi.org/10.1038/bjc.1990.62
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- ONDANSETRON WITH AND WITHOUT DEXAMETHASONE TO TREAT CHEMOTHERAPY-INDUCED EMESISThe Lancet, 1989
- Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy.Journal of Clinical Oncology, 1988
- PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONISTThe Lancet, 1987
- 5-hydroxytryptamine m-receptor antagonism to prevent cisplatin-induced emesisNeuropharmacology, 1986
- Inhibition of cisplatin‐induced vomiting by selective 5‐hydroxytryptamine M‐receptor antagonismBritish Journal of Pharmacology, 1986
- Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patientsCancer, 1985